Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)

NCT05686642 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT05686642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
April 6, 2023
Completion date
December 12, 2026
Enrollment
300 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke